Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

H. Lundbeck A Director's Dealing 2016

May 12, 2016

Preview isn't available for this file type.

Download source file

Valby, Denmark, 2016-05-12 17:15 CEST (GLOBE NEWSWIRE) -- Valby, Denmark, 12
May 2016 - H. Lundbeck A/S (Lundbeck) hereby reports transactions made by
executives and persons and legal entities closely associated to them with
shares and linked securities in Lundbeck, cf. Section 28a of the Danish
Securities Trading Act.

As part of Lundbeck’s long-term incentive programmes for 2009, 2010, 2011, 2012
and 2014 the below mentioned executive has exercised warrants.

Name:
Anders Gersel Pedersen

Job position:
Executive Vice President, member of the Executive Management

ID code (ISIN code): DK
0010287234

Name of the issuer of the securities: H.
Lundbeck A/S

Description of the security:
Warrants

Nature of the transaction:
Exercise of warrants

Date of trading:
12 May 2016

Market on which the trading was affected: Nasdaq OMX
Copenhagen

Number of traded securities: 42,478

Total market price of securities traded: DKK
10,258,437

Name:
Anders Gersel Pedersen

Job position:
Executive Vice President, member of the Executive Management

ID code (ISIN code):
DK 0010287234

Name of the issuer of the securities: H.
Lundbeck A/S

Description of the security:
Warrants

Nature of the transaction:
Exercise of warrants

Date of trading:
12 May 2016

Market on which the trading was affected: Nasdaq OMX
Copenhagen

Number of traded securities: 8,318

Total market price of securities traded: DKK
2,008,797

Persons under obligation to report such transactions are defined as members of
the Executive Management, members of the Board of Directors and other
executives of H. Lundbeck A/S and persons/entities closely associated to them.

Closely associated persons/entities could include but is not limited to:

• spouse or cohabitant

• children below the age of 18, provided that the executive is
the custody holder

• legal entities in which the executive has a controlling
influence

Lundbeck contacts

Investors: Media:

Palle Holm Olesen Mads Kronborg
Vice President, Investor Relations Senior Director, Corp. Communication
[email protected] [email protected]
+45 30 83 24 26 +45 36 43 30 00

About H. Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company
specialized in psychiatric and neurological disorders. For more than 70 years,
we have been at the forefront of research within neuroscience. Our key areas of
focus are depression, schizophrenia, Parkinson's disease and Alzheimer's
disease.

An estimated 700 million people worldwide are living with psychiatric and
neurological disorders and far too many suffer due to inadequate treatment,
discrimination, a reduced number of working days, early retirement and other
unnecessary consequences. Every day, we strive for improved treatment and a
better life for people living with psychiatric and neurological disorders – we
call this Progress in Mind.

Our approximately 5,300 employees in 55 countries are engaged in the entire
value chain throughout research, development, manufacturing, marketing and
sales. Our pipeline consists of several late-stage development programmes and
our products are available in more than 100 countries. We have research centres
in China and Denmark and production facilities in China, Denmark, France and
Italy. Lundbeck generated core revenue of DKK 14.6 billion in 2015 (EUR 2
billion; USD 2.2 billion).

For additional information, we encourage you to visit our corporate site
www.lundbeck.com and connect with us on Twitter at @Lundbeck.